Market atlas / Amino-acid / glutathione / Glycine

Glycine (amino acid, GlyNAC)

traditional-to-validatedsmall-moleculeglutathione-synthesisamino-acid● glutathione

Stage by geography

signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUSSGIL+3 stages

MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS

What each market approved it for

Market	Stage	Since	Indication / class / form
US	consumer	not dated	not published
SG	signal	not dated	not published
IL	RCT	not dated	not published

Biomarker trends

no biomarker readings yet

Studies

The studies on Glycine, what they found, in whom and how strongly, are on its evidence page, each linked to its source.

What the trials measure

Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.

Registered primary endpoint	Markets measuring it
Scale of Prodromal Symptoms Total Score	US
Change in Scale of Prodromal Symptoms Total Score	US
Part A: Safety and tolerability endpoints consisting of: adverse events; 12-lead ECG; vital signs, clinical laboratory…	US
Part B: Midazolam PK following single and repeat doses of GSK1018921.	US
Part C: Plasma & CSF glycine concentrations following single doses og GSK1018921.	US
Part D: Safety and tolerability endpoints consisting of: adverse events; 12-lead ECG; vital signs, clinical laboratory…	US
Muscle glutathione concentration	US
Phase I: Number of Grades 1, 2, 3, 4, and/or 5 and Type of Serious and/or Non-serious Toxicities Experienced by Participants at…	US
Phase I: Percentage of Participants Who Experienced a Grade 3, 4 and/or 5 Serious Dose-Limiting Toxicity (DLT) Reported With Type…	US
Phase II: Percentage of Participants With a Clinical Response (Complete Response (CR) + Partial Response (PR) Reported With 80%…	US

Connections

no connections yet

Trajectory

2020

ProfileGlycine (amino acid, GlyNAC)

NCT04738422 · machine-extracted

2020

MarketUS: rct (clinical trials (highest phase 2))

NCT04738422 · machine-extracted

2026

MarketUS: consumer (US dietary supplement (DSHEA), not FDA-approved as a drug)

DSLD:14922 · machine-extracted

2026

MarketIL: rct (clinical trials (highest phase 2))

NCT00276263 · machine-extracted

2026

MarketSG: signal (clinical trials (highest phase ?))

NCT04658134 · machine-extracted

Get into the weeds: raw observations + provenance

gly_facets  2026-06-29  kind=facets  verify=M
   Glycine facets
   source NCT04738422  https://clinicaltrials.gov/study/NCT04738422

gly_us_trial  2026-06-29  kind=geography_stage  verify=M
   Glycine (as GlyNAC): US phase 2 trials [NCT04738422]
   source NCT04738422  https://clinicaltrials.gov/study/NCT04738422

gly_us_consumer  2026-06-29  kind=geography_stage  verify=M
   Glycine sold as a US dietary supplement
   source DSLD:14922  https://dsld.od.nih.gov/label/14922

ctsearch__IL__dev_glycine  2026-07-10  kind=geography_stage  verify=M
   glycine: 2 registered trial(s) in IL, highest phase 2 [NCT00276263]
   source NCT00276263  https://clinicaltrials.gov/study/NCT00276263

ctsearch__SG__dev_glycine  2026-07-10  kind=geography_stage  verify=M
   glycine: 1 registered trial(s) in SG, highest phase ? [NCT04658134]
   source NCT04658134  https://clinicaltrials.gov/study/NCT04658134